The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Proper survival and regeneration of retinal ganglion cells (RGCs), which constitute the optic nerve, is crucial for managing traumatic or ischemic optic nerve injury, optic neuropathy, or optic ...

An award-winning presentation during the 2023 ARRS Annual Meeting explained how the novel technique of three-dimensional (3D) slice-to-volume (SVR) MRI allows for precise delineation and measurement ...

About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic ...

Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...

Optic atrophy is a condition in which the optic nerve begins to deteriorate. The optic nerve is the nerve at the back of your eye that connects your eye to your brain, allowing you to see. There are a ...

What Is Optic Nerve Drusen? Optic nerve drusen is a rare eye condition that affects between 3 and 24 people out of every 1,000 in the population. It’s difficult to estimate exactly how common this ...

The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...